快要 飞的 《药股》 讨论区

m.i.k.e

原帖由 葉芬 于 17-11-2009 11:43 PM 发表




HLCS 麥麥叫買很久下了。。。

她的是收到今天，前幾天股價跌再加碼。。。

真的是"鸡婆".....
不过,还是要谢谢你帮我出面.

你有再买回吗?

葉芬

麥麥，你的HLCS昨晚走勢 Thumb Up。。。

只要HLCS有賣到1架Machine，股價就會上。。。

葉芬

原帖由 m.i.k.e 于 18-11-2009 10:18 AM 发表
真的是"鸡婆".....
不过,还是要谢谢你帮我出面.

你有再买回吗?

呵呵 我目前Fund不夠，所以還沒有輪到 HLCS。。。
*目前要買的
CVM （加碼）
MPEL （要買）
BDSI（要買- 昨晚排4.43 沒做到，做到別人的而已！）


其他的在投機帖裏Post 的是賺了就走人的

m.i.k.e

原帖由 葉芬 于 18-11-2009 10:25 AM 发表




呵呵 我目前Fund不夠，所以還沒有輪到 HLCS。。。
*目前要買的
CVM （加碼）
MPEL （要買）
BDSI（要買- 昨晚排4.43 沒做到，做到別人的而已！）


其他的在投機帖裏Post 的是賺了就走人的

看来,你会再次错失和我双飞双....的机会.

MPEL （要買） - 你要等$4....还有排.....我看你先把资金借给我比较好.
BDSI（要買- 昨晚排4.43 沒做到，做到別人的而已！） - 这股有什么东西好期待???

葉芬

原帖由 m.i.k.e 于 18-11-2009 10:35 AM 发表


看来,你会再次错失和我双飞双....的机会.

MPEL （要買） - 你要等$4....还有排.....我看你先把资金借给我比较好.
BDSI（要買- 昨晚排4.43 沒做到，做到別人的而已！） - 这股有什么东西好期待???

你的HLCS應該今晚還有看頭。。。

因為

Events & Tradeshows

                                    Advances in Gene Expression Profiling

Date:            Nov. 18, 2009	Website:	Event Website
Location:            Philadelphia, PA	Venue:	Crowne Plaza, City Center

Presentation:
4:30 PM, "Single Molecule Sequencing for Unbiased Views of Gene Expression from Small Numbers of Cells", Dr.John Thompson






我也許會投機下。看今晚情形怎樣。

葉芬

Future Up 1.00 Point

YMZ09.CBT        Mini Dow Jones Indus.-$5 Dec 09        10,399.00  3:35am ET        Up 1.00 (0.01%)




XXXXXXXXXXXXXXXXXXXXXXXXXXX


忘了 恭喜    麥麥 成功放上頭像。。

[ 本帖最后由 葉芬 于 18-11-2009 04:49 PM 编辑 ]

葉芬

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized
H1N1 Infected Patients at Johns Hopkins University School of Medicine

Wed Nov 18 09:45:00 2009
EST
VIENNA, Va., Nov 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics
for the prevention and treatment of infectious diseases and a late-stage oncology
company, announced today the start of the Company's first clinical study for hospitalized
H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins).
The study is being led by Principal Investigator Jonathan M. Zenilman, MD, Professor
of Medicine, Johns Hopkins School of Medicine and Chief of Infectious Diseases Division,
Johns Hopkins Bayview Medical Center.  This initial study will involve taking blood
from 20 hospitalized, laboratory-confirmed H1N1 patients and activating their cells
with the LEAPS-H1N1 investigational therapy in order to assess the cells' response
as the basis for the planned future treatment of this patient population under a
next-stage clinical trial protocol.  In parallel, the study will involve taking
blood from 20 healthy individuals not infected with H1N1 and activating their cells
with the LEAPS-H1N1 investigational therapy to serve as a control for the patient
group in the study.
In September, the Company announced that the FDA had indicated that the Company
could commence this study.  In order for FDA to fully consider a next-stage clinical
trial to evaluate LEAPS-H1N1 treatment of hospitalized patients with laboratory-confirmed
H1N1 Pandemic Flu under an Exploratory IND, FDA has asked CEL-SCI to submit a detailed
follow-up regulatory filing with extensive additional data.
"We are pleased that we have been able to move so fast with this first study
of our LEAPS-H1N1 treatment," said Geert Kersten, CEL-SCI's Chief Executive Officer.
"As we move forward, we hope that our investigational immunotherapy can be shown
to modulate patients' immune responses to be effective without the cytokine storm
that CEL-SCI's scientists believe may be responsible for so many deaths."
The initiation of CEL-SCI's rapidly-accelerated LEAPS-H1N1 clinical development
program builds on CEL-SCI's pioneering work with its LEAPS technology in the context
of H1N1.  CEL-SCI's L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System)
technology allows the Company to direct an immune response against specific disease
epitopes.  In the case of CEL-SCI's investigational LEAPS-H1N1 treatment, this involves
non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu.
This is intended to enable stimulation of the specifically-needed immune responses,
while avoiding the administration of regions of H1N1, and other viruses, which may
exacerbate the problem of cytokine storm, which CEL-SCI scientists believe may be
involved in the death of some H1N1 patients.
L.E.A.P.S. technology is a novel T-cell modulation platform technology that
enables CEL-SCI to design and synthesize, non-recombinantly, proprietary immunogens.
The L.E.A.P.S. technology combines a small peptide that activates the immune system
with a small peptide from a disease-related protein, such as the H1N1 hemagglutinin
molecule, to make an investigational product that induces defined immune responses.
Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which previously
has demonstrated the ability to induce and elicit protective immunity and antigen-specific
antibody production in animal models.  Thus, extensive animal studies conducted
to date indicate that any disease for which an antigenic sequence has been identified,
such as infectious, parasitic, malignant or autoimmune diseases and allergies, are
potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses.
Its lead product is Multikine((R)) which is being readied for a global Phase III
trial in advanced primary head and neck cancer.  CEL-SCI is also developing an immunotherapy
to prevent and treat swine and other influenzas using its L.E.A.P.S. technology
platform and expects to soon finish the validation of its state-of-the-art facility
in Maryland which it expects to utilize to launch aseptic filling for stem cell
produced therapies and other biological products. The Company has operations in
Vienna, Virginia, and Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
When used in this report, the words "intends," "believes," "anticipated"
and "expects" and similar expressions are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties which could cause actual
results to differ materially from those projected. Factors that could cause or contribute
to such differences include, lack of regulatory clearance to proceed with clinical
trials, an inability to duplicate the clinical results demonstrated in clinical
studies that have been completed or that are initiated in the future, timely development
of any potential products that can be shown to be safe and effective, unwillingness
of regulatory authorities to engage in further regulatory dialogue, receiving necessary
regulatory approvals, difficulties in manufacturing any of the Company's potential
products, inability to raise the necessary capital, and the risk factors set forth
from time to time in CEL-SCI Corporation's SEC filings, including but not limited
to its report on Form 10- K/A for the year ended September 30, 2008. The Company
undertakes no obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE  CEL-SCI Corporation
http://www.cel-sci.com
Copyright (C) 2009 PR Newswire. All rights reserved

CVM,

葉芬

CVM  UP ... Now...

miku

好像慢热。。。。。。

葉芬

原帖由 miku 于 18-11-2009 11:04 PM 发表
好像慢热。。。。。。

也是有這樣的感覺。。。。

tankangkai

我买的MDCO从6.70 上到12没放，现在已经下到7++...

葉芬

原帖由 tankangkai 于 19-11-2009 06:33 AM 发表
我买的MDCO从6.70 上到12没放，现在已经下到7++...

超過100%了都不Take Profit？？

這就是我常常說的要設止贏點 。。。 沒法子。。


P/s: 再回味下這句話的意思。。 這句話的意思很深。。
Realize your profit before you Realize you lost it...

葉芬

http://vfcsstockhouse.blogspot.c ... rs-respond-cvm.html

Wednesday, November 18, 2009
Readers Respond: CVM


CVM: A comment from Michael regarding Cel Sci Corp.:

Hi VFC

I first heard about CVM from one of your articles on SeekingAlpha. After that I did my own DD on CVM and have since taken a position in it because I believe the risk/reward is definitely worth the amount of money I'm putting in it. I'm definitely willing to lose the money I put in b/c I feel that if Multikine succeeds, this stock will easily follow Dendreon.

However, I'm not a science guy (I'm an accountant and more of a finance guy) and thus I don't know much about how the FDA works. My question is basically what is the difference between phase 2 and 3? I saw the CVM November Powerpoint on their site and they said they avoided many of the problems other companies ran into. However, even so, I am wondering what the chances are that Phase 3 succeeds? Is it 50/50? 60/40? In other words, if phase 2 was such a success, what could go WRONG in phase 3 for Multikine to not get FDA approval?

I first bought in at $1.5 and have been averaging down happily...I'm hoping it falls below $1 again so I can load up the boat. Thanks for your insight VFC and I hope you're right on CVM.

PS: I read the Yahoo Message Boards daily and they are very entertaining. A lot of people are saying how Byron is fake and how CVM hasn't delivered since inception. Any comments on those. Thanks.

Michael

VFC's Take: I agree that CVM is still worth the risk/reward right now, even for those that are just now gaining a position in the stock. If Multikine is proven successful in Phase III trials, I think that Cel Sci will not only follow Dendreon (DNDN), but probably surpass it. Multikine, unlike Dendreon's Provenge, is being developed as a first-line standard of care.

However, before we get too excited, we all must remember to temper our expectations of success until we start seeing some results from the Phase III trial which haven't even started yet.

The main difference between a Phase II and Phase III trial is the scope and size of the trial. In short, Phase I generally tests the safety of a potential product; Phase II is a continuation of safety studies in a larger patient group, but mainly is used to see if the product actually works; Phase III is the 'make or break' trial - the potential product candidate is tested in a much larger group of patients. The trial not only confirms how well the potential product works, but also measures how much (if at all) better it is than what's already out there. That's just VFC's brief description of the clinical trials, a Google search will most definitely provide you with more detail.

As for the chances of a Multikine Phase III success, I'm not in a medical position to place an estimate based on 'percentage of success', I can only account for what I read and/or discuss with people in the medical (cancer) field, but I like what I have seen enough to consider the risk of an investment in CVM to be well worth the possible rewards.

Each investor will have to determine for his or herself how much money is worth risking in an investment based on his or her own financial situation, stomach for risk and - most importantly - their own DD.

I do know that Cel Sci has been in contact with the FDA reguarly regarding the development of Multikine and the Multikine manufacturing facility near Baltimore, Maryland (after all, the FDA gave Cel Sci the go-ahead to move forward with the Phase III trial), but as far as what can go wrong - I can only speculate. If Multikine does not work, that would certainly be a show-stopper, and every investment comes with the inherent risk that the stock will go to zero; CVM is no different. Multikine is no sure thing, but all indications so far is that it works, so I like my chances with this one.

As far as anything going wrong with the production of Multikine, Cel Sci has taken precaution after precaution to ensure that nothing goes wrong inside that facility. There are double-checks and repetitive measures in place that will virtually guarantee a smooth operation of production.

Now, addressing the message board fodder that you speak of, I'd have to believe that Byron is somebody - somebody owns the Multikine rights to South Africa. I can speculate as to who that 'somebody' is all day long, but in my opinion, it has no bearing on whether or not I deem Multikine or LEAPS - the real bread in the Cel Sci basket - to be successful.

Byron could be Jimmie "Spoons" selling a Rolex on my street corner and I couldn't care less; but if Multikine is successful and enters the South African head and neck cancer market, then I expect that Jimmie "Spoons" is going to be rich.

And the 'not delivered' question has no bearing. It takes years, sometimes decades for great products to get to market. Those shareholders that were loading up on Cel Sci for thirty cents would also disagree that it has not delivered.

Every investment that you make should come with an entry and exit strategy. Your exit strategy should specify which events would cause you to sell. If you exit your position in the stock for less than what you bought it, then you could say that that investment did not deliver.

My exit strategy with Cel Sci has nothing to do with Byron and Yahoo! message boards and everything to do with Multikine, LEAPS and the cold-fill contracting service that Cel Sci will soon provide.

We have only seen the tip of the iceberg on all three, in my opinion, so it's way too early to claim a non-delivery from Cel Sci. There are plenty of posters on the

Thank you for reading and as always, each investor should do their own DD and invest accordingly.

Disclosure: VFC is long CVM.

葉芬

今天Future.。。。

YMZ09.CBT        Mini Dow Jones Indus.-$5 Dec 09        10,383.00  2:14am ET        Down 21.00 (0.20%)       


XXXXXXXXXXXXXXXXXXXXXXXXX


雖然說昨晚的CVM有好消息，股價卻沒有什么上。
不過她在1.3多的價錢穩住超過7天啦。。不錯的現象。

tankangkai

原帖由 葉芬 于 19-11-2009 09:23 AM 发表




超過100%了都不Take Profit？？

這就是我常常說的要設止贏點 。。。 沒法子。。


P/s: 再回味下這句話的意思。。 這句話的意思很深。。
Realize your profit before you Realize you lost it...

都是贪咯，想要在15usd才出货，虽然我只是买1000股,但扣除汇率的差别，纸上盈利也有6-7K新币！

葉芬

原帖由 tankangkai 于 19-11-2009 08:15 PM 发表

都是贪咯，想要在15usd才出货，虽然我只是买1000股,但扣除汇率的差别，纸上盈利也有6-7K新币！

要是有6-7千新幣也不錯。。。

賣後等她跌了再買回也可以。

miku

太贪心太贪心了。。以前我10.41买kndl，起到16没卖，又跌到10.xx，没赚卖掉，现在又17了。。。

浪费时间！！

tankangkai

原帖由 miku 于 19-11-2009 09:30 PM 发表
太贪心太贪心了。。以前我10.41买kndl，起到16没卖，又跌到10.xx，没赚卖掉，现在又17了。。。

浪费时间！！

真的是one point lesson 咯

miku

cvm 天跌破1.23我买。

葉芬

原帖由 miku 于 19-11-2009 10:08 PM 发表
cvm 天跌破1.23我买。

我每天都有排。。 1.02 及 1.25